论文部分内容阅读
目的探究肿瘤标志物CA724、CEA、CA242、CA199在胃癌检验中的临床应用价值。方法选取本院2015年2月到2016年2月收治胃癌患者450例作为胃癌组,选取同期患其他胃部疾病患者450例作为对照组。对900例患者进行肿瘤标志物CA724、CEA、CA242、CA199的联合检验,并与病理结果分析其检验结果。结果胃癌组联合检测结果高于对照组,对比显示具有统计学意义(P<0.05);胃癌组Ⅰ期、Ⅱ期、Ⅲ期肿瘤标志物联合检验阳性率优于单项检验阳性率,对比显示存在统计学意义(P<0.05)。结论肿瘤标志物CA724、CEA、CA242、CA199可有效帮助胃癌患者及早确诊病情。
Objective To investigate the clinical value of tumor markers CA724, CEA, CA242 and CA199 in gastric cancer. Methods A total of 450 patients with gastric cancer admitted from February 2015 to February 2016 in our hospital were enrolled as gastric cancer group. 450 patients with other gastric diseases in the same period were selected as the control group. Ninety-nine patients were tested for the combination of tumor markers CA724, CEA, CA242 and CA199, and the results of pathology were analyzed. Results The results of combined detection in gastric cancer group were higher than those in control group (P <0.05). The positive rates of combined detection of tumor markers in stage Ⅰ, Ⅱ and Ⅲ of gastric cancer group were better than those of single test, and the comparison showed that there was Statistical significance (P <0.05). Conclusion The tumor markers CA724, CEA, CA242 and CA199 can effectively help patients with gastric cancer diagnosed as soon as possible.